Prostate Cancer P D:前列腺易感位点的生殖系变异不能预测化学预防试验PCPT和SELECT中的结果

2019-12-13 AlexYang MedSci原创

前列腺癌的发展受遗传和环境因素的影响,大量的生殖系SNPs能够影响前列腺癌的易感性,而这些SNPs是通过怎样的功能途径来增加前列腺癌易感性的仍旧未知。Finasteride目前不作为化学预防药物,但是PCPT试验的长期结果仍旧是人们期待的。SELECT试验结果并未推荐使用化学预防药物来预防前列腺癌。最近,有研究人员调查了是否生殖系风险SNPs可以用来预测PCPT和SELECT试验的结果。研究人员对

前列腺癌的发展受遗传和环境因素的影响,大量的生殖系SNPs能够影响前列腺癌的易感性,而这些SNPs是通过怎样的功能途径来增加前列腺癌易感性的仍旧未知。Finasteride目前不作为化学预防药物,但是PCPT试验的长期结果仍旧是人们期待的。SELECT试验结果并未推荐使用化学预防药物来预防前列腺癌。最近,有研究人员调查了是否生殖系风险SNPs可以用来预测PCPT和SELECT试验的结果。

研究人员对参与研究的欧洲男性进行基因分型,PCPT试验包括2434名男性,SELECT试验中包括4885名男性。研究发现,在100个SNPs位点中,成功设计了98个,基因分型数据在其他的平台进行验证。研究发现,在2个试验中,许多的SNPs能够预测恶性疾病。那些具有更高多基因得分的男性在2个试验中均更可能发展为前列腺癌,而评分并没有用于预测其他的结果。

最后,研究人员指出,具有更高多基因得分的男性更可能发展为前列腺癌。另外,在PCPT试验和SELECT试验中,生殖系风险SNPs与化学预防药物没有相互关系。

原始出处:

Mahbubl Ahmed, Chee Goh, Edward Saunders et al. Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate Cancer P D. 27 Nov 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2020-08-19 周虎
  4. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2020-06-22 DEXTER3139
  5. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-15 lsndxfj
  8. [GetPortalCommentsPageByObjectIdResponse(id=2019029, encodeId=6c22201902917, content=<a href='/topic/show?id=64fe59656df' target=_blank style='color:#2F92EE;'>#易感位点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59656, encryptionId=64fe59656df, topicName=易感位点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Aug 11 04:38:00 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791597, encodeId=ecb81e915976d, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Jul 21 10:38:00 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1945759, encodeId=b5b61945e5911, content=<a href='/topic/show?id=febb691021d' target=_blank style='color:#2F92EE;'>#生殖系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69102, encryptionId=febb691021d, topicName=生殖系)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Wed Aug 19 02:38:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011729, encodeId=7cc72011e2940, content=<a href='/topic/show?id=7e89138666b' target=_blank style='color:#2F92EE;'>#PCP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13866, encryptionId=7e89138666b, topicName=PCP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Mon Jun 22 16:38:00 CST 2020, time=2020-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793711, encodeId=7aa71e9371198, content=<a href='/topic/show?id=19c2161119c' target=_blank style='color:#2F92EE;'>#SeLECT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16111, encryptionId=19c2161119c, topicName=SeLECT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Sat Dec 28 06:38:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342626, encodeId=59ae134262658, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364551, encodeId=83db136455141, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602220, encodeId=fbe2160222094, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Dec 15 04:38:00 CST 2019, time=2019-12-15, status=1, ipAttribution=)]
    2019-12-15 sunylz

相关资讯

J Clin Oncol:派姆单抗治疗难治性转移去势抵抗性前列腺癌研究

之前的研究报道了派姆单抗对程序性死亡配体1(PD-L1)阳性转移去势抵抗性前列腺癌(mCRPC)具有抗肿瘤活性。最近,有研究人员评估了派姆单抗在一个更大的mCRPC群体中的3个平行群体中的抗肿瘤活性和安全性情况。研究共包括了258名患者:群体1中包含133名,群体2中包含66名,群体3中包含59名。群体1中客观反映率为5%(95% CI, 2%到11%),群体2中客观反映率为3%(95% CI,

转移性前列腺癌该如何化疗

自2004年TAX327研究证实多西他赛联合泼尼松较米托蒽醌联合泼尼松方案显着延长mCRPC患者者总生存时间以来,多西他赛化疗在转移性前列腺癌的治疗中发挥着越来越重要的作用。

Nat Commun:转移趋势抵抗性前列腺癌基因组图谱阐释了不同的基因型具有可能的临床影响

转移去势抵抗性前列腺癌(mCRPC)具有高度复杂的基因组图谱。随着最近新治疗方法的发展,对前列腺癌的精准分层策略是需要的。最近,有研究人员对197名mCRPC患者的新鲜冷冻转移活检样本进行了全基因组测序(WGS)分析。基于基因组特性的无监督聚类分析,研究人员确定了8个不同的基因组聚类。研究人员观察到了可能的临床相关基因型,包括微卫星不稳定性(MSI)、基因组缺失中富集的同源重组缺失(HRD)、BR

Prostate Cancer P D:前列腺癌肿瘤内治疗的一种多聚糊状药物配方

重点治疗已经成为低到中等风险局部前列腺癌(PCa)患者的一种治疗选择,该治疗方法能够平衡根治性治疗方法的泌尿和性功能并发症风险,以及积极监测带来的精神负担。最近,有研究人员开发了一种包含了多烯紫杉醇(dtx)和比卡鲁胺(bic)的可注射的多聚糊状制剂ST-4PC,可用于成像指导的PCa重点治疗。他们的目的是评估ST-4PC的体内和体外治疗效果和安全性。研究发现,ST-4PC药物在注射14天后能够持

Eur Urol:局部前列腺癌患者中的10年死亡率、疾病恶化和治疗相关副作用分析

ProtecT试验报道了局部前列腺癌男性的意向分析,他们随机的分配到积极监控(AM)、根治性前列腺切除和体外放射治疗中。最近,有研究人员在随机和治疗选择群体中,报道了接受不同治疗的男性的结果情况。研究发现,根据接受治疗的方法,接受AM的男性死亡率更高(AM,1.85%;手术,0.67%;放疗,0.73%),而该差异在随机群体中仍旧保持一致(p=0.08);在AM与组合放疗比较的探索性分析中,研究人

Sci Rep:全外显子罕见变异分析鉴定了3个新的前列腺癌诱发性基因

由于前列腺癌是高度可遗传的,与前列腺癌相关的常见变异已经在各种群体中有所研究,包括了韩国群体。然而,稀有的和低频变异对疾病的遗传也具有明显的影响。到目前为止,韩国群体中稀有变异对前列腺癌易感性的贡献情况还没有系统的评估。最近,有研究人员对7258名个体(985个前列腺癌案例和6273名对照)进行了大规模的全外显子组稀有变异分析。研究总共发现了19个稀有变异位点,覆盖了7个基因,且与前列腺癌的易感性